-
EP2493503
European procedure
Extract from the Register of European Patents
EP About this file: EP2493503
| EP2493503 - DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY [Right-click to bookmark this link] | Status | Patent maintained as amended Status updated on 18.12.2020 Database last updated on 02.11.2024 | Most recent event Tooltip | 18.12.2020 | Patent maintained (B2 publication) | published on 20.01.2021 [2021/03] | Applicant(s) | For all designated states Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 München / DE | [2021/03] |
| Former [2012/36] | For all designated states Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 München / DE | Inventor(s) | 01 /
NAGORSEN, Dirk c/o Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 Munich / DE | 02 /
KUFER, Peter c/o Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 Munich / DE | 03 /
ZUGMAIER, Gerhard c/o Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 Munich / DE | 04 /
BAEUERLE, Patrick c/o Amgen Research (Munich) GmbH Staffelseestrasse 2 81477 Munich / DE | [2015/32] |
| Former [2012/36] | 01 /
NAGORSEN, Dirk c/o Micromet AG Staffelseestrasse 2 81477 Munich / DE | ||
| 02 /
KUFER, Peter c/o Micromet AG Staffelseestrasse 2 81477 Munich / DE | |||
| 03 /
ZUGMAIER, Gerhard c/o Micromet AG Staffelseestrasse 2 81477 Munich / DE | |||
| 04 /
BAEUERLE, Patrick c/o Micromet AG Staffelseestrasse 2 81477 Munich / DE | Representative(s) | Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE | [2021/03] |
| Former [2015/33] | Schiweck, Weinzierl & Koch European Patent Attorneys Landsberger Straße 98 80339 München / DE | ||
| Former [2012/36] | Schiweck, Weinzierl & Koch European Patent Attorneys Landsberger Straße 98 80339 München / DE | Application number, filing date | 10771102.0 | 27.10.2010 | [2015/33] | WO2010EP66207 | Priority number, date | EP20090174104 | 27.10.2009 Original published format: EP 09174104 | US20090255290P | 27.10.2009 Original published format: US 255290 P | [2012/36] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2011051307 | Date: | 05.05.2011 | Language: | EN | [2011/18] | Type: | A1 Application with search report | No.: | EP2493503 | Date: | 05.09.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.05.2011 takes the place of the publication of the European patent application. | [2012/36] | Type: | B1 Patent specification | No.: | EP2493503 | Date: | 12.08.2015 | Language: | EN | [2015/33] | Type: | B2 New European patent specification | No.: | EP2493503 | Date: | 20.01.2021 | Language: | EN | [2021/03] | Search report(s) | International search report - published on: | EP | 05.05.2011 | Classification | IPC: | A61K39/00, C07K16/28, G01N33/50 | [2015/08] | CPC: |
C07K16/2809 (EP,CN,KR,US);
A61K39/395 (KR);
C07K16/2803 (EP,CN,KR,US);
A61P25/00 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
G01N33/505 (EP,CN,KR,US);
G01N33/5052 (EP,CN,KR,US);
G01N33/5094 (KR,US);
A61K2039/505 (EP,CN,KR,US);
A61K2039/545 (EP,CN,KR,US);
A61K2039/55 (EP,CN,KR,US);
|
| Former IPC [2012/36] | A61K39/395, C07K16/46, G01N33/574 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/36] | Extension states | BA | 29.05.2012 | ME | 29.05.2012 | Title | German: | DOSIERSCHEMA ZUR VERABREICHUNG EINES CD19XCD3 BISPEZIFISCHES ANTIKÖRPERS. | [2015/08] | English: | DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY | [2012/36] | French: | POSOLOGIE D'ADMINISTRATION D'UN ANTICORP CD19XCD3 BISPECIFIIQUE | [2015/08] |
| Former [2012/36] | DOSIERPLAN ZUR VERABREICHUNG EINES BISPEZIFISCHEN CD19XCD3-ANTIKÖRPERS | ||
| Former [2012/36] | POSOLOGIE ASSOCIÉE À L'ADMINISTRATION D'UN ANTICORPS BISPÉCIFIQUE CD19XCD3 | Entry into regional phase | 29.05.2012 | National basic fee paid | 29.05.2012 | Designation fee(s) paid | 29.05.2012 | Examination fee paid | Examination procedure | 29.05.2012 | Amendment by applicant (claims and/or description) | 29.05.2012 | Examination requested [2012/36] | 24.07.2013 | Despatch of a communication from the examining division (Time limit: M06) | 03.02.2014 | Reply to a communication from the examining division | 30.05.2014 | Despatch of a communication from the examining division (Time limit: M04) | 24.09.2014 | Reply to a communication from the examining division | 17.02.2015 | Communication of intention to grant the patent | 29.06.2015 | Fee for grant paid | 29.06.2015 | Fee for publishing/printing paid | 29.06.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.07.2013 | Opposition(s) | Opponent(s) | 01
12.05.2016
08.08.2019
WITHDRAWN Affimed GmbH Technologie Park Im Neuenheimer Feld 582 69120 Heidelberg / DE Opponent's representative Schmitz, Georg Huber & Schüssler Patentanwälte Truderinger Strasse 246 81825 München / DE | [2019/38] |
| Former [2016/27] | |||
| Opponent(s) | 01
12.05.2016
30.05.2016
ADMISSIBLE Affimed GmbH Technologie Park Im Neuenheimer Feld 582 69120 Heidelberg / DE Opponent's representative Schmitz, Georg Huber & Schüssler Patentanwälte Truderinger Strasse 246 81825 München / DE | 22.06.2016 | Invitation to proprietor to file observations on the notice of opposition | 23.12.2016 | Reply of patent proprietor to notice(s) of opposition | 22.03.2018 | Date of oral proceedings | 13.07.2018 | Despatch of minutes of oral proceedings | 17.07.2018 | Despatch of interlocutory decision in opposition | 08.10.2020 | Legal effect of interlocutory decision in opposition | 16.10.2020 | Despatch of communication that the patent will be maintained as amended | 09.12.2020 | Fee for printing new specification paid | Appeal following opposition | 27.09.2018 | Appeal received No. T2425/18 | 27.11.2018 | Statement of grounds filed | 08.10.2020 | Result of appeal procedure: appeal of the proprietor withdrawn | 24.09.2018 | Appeal received No. T2425/18 | 27.11.2018 | Statement of grounds filed | 08.10.2020 | Result of appeal procedure: appeal of the proprietor withdrawn | Fees paid | Renewal fee | 23.10.2012 | Renewal fee patent year 03 | 24.10.2013 | Renewal fee patent year 04 | 14.10.2014 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 12.08.2015 | IS | 13.06.2016 | [2018/47] |
| Former [2016/38] | IS | 13.06.2016 | Cited in | International search | [XDA]WO9954440 (DOERKEN BERND [DE], et al) [XD] 40,41 * claims 1-16, 21-26 * [A] 1-39,42-44; | [X]WO2004106381 (MICROMET AG [DE], et al) [X] 40,41 * claim 1 *; | [XA]WO2007068354 (MICROMET AG [DE], et al) [X] 40,41 * page 19, paragraph 2 - page 20, line 5 *[A] 1-39,42-44; | [AD] - BARGOU RALF ET AL, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.", SCIENCE (NEW YORK, N.Y.) 15 AUG 2008 LNKD- PUBMED:18703743, (20080815), vol. 321, no. 5891, ISSN 1095-9203, pages 974 - 977, XP002615656 [AD] 1-44 * page 976, column middle * DOI: http://dx.doi.org/10.1126/SCIENCE.1158545 | by applicant | WO9954440 | EP0623679 | WO2004106381 | WO2007068354 | WO2008119565 | - BARGOU ET AL., SCIENCE, (2008), vol. 321, pages 974 - 7 | - ARTHRITIS RHEUM., (200602), vol. 54, no. 2, pages 613 - 20 | - MOSTELLER, N ENGL J MED, (19871022), vol. 317, no. 17, page 1098 | - DUBOIS, ARCH INT MED, (1916), vol. 17, pages 863 - 871 | - HAYCOCK, THE JOURNAL OF PEDIATRICS, (1978), vol. 93, no. 1, pages 62 - 66 | - GEHAN, CANCER CHEMOTHER REP, (1970), vol. 54, pages 225 - 35 | - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, pages 443 - 453 | - SMITH; WATERMAN, ADV. APPL. MATH, (1981), vol. 2, pages 482 - 489 | - CRICK, J MOL BIOL, (1966), vol. 19, pages 548 - 55 | Opposition | WO2007068354 | WO2008119567 | - KLINGER MATTHIAS, "Wirkmechanismus des bispezifischen anti-CD19 x anti-CD3 BiTE-Antikörpers MT103 in Patienten mit rezidivem indolenten B-Zell-Non-Hodgkin-Lymphom", Dissertation Universität Tübingen, (20090000), pages 1 - 115, XP055288098 | - NAGORSEN, D et al., "Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab", Leukemia & lymphoma, (20090000), vol. 50, no. 6, pages 886 - 91, XP008128752 DOI: http://dx.doi.org/10.1080/10428190902943077 | - AMANN, M et al., "Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans", Cancer Immunology Immunotherapy, (20090000), vol. 58, no. 1, pages 95 - 109, XP019654574 | - KLINGER MATTHIAS, "Wirkmechanismus des bispezifischen anti-CD19 x anti-CD3 BiTE-Antikörpers MT103 in Patienten mit rezidivem indolenten B-Zell-Non-Hodgkin-Lymphom", Dissertation Universität Tübingen, (20090000), pages 1 - 115 | - NAGORSEN, D et al., "Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab", Leukemia & lymphoma, (20090000), vol. 50, no. 6, pages 886 - 91 | - AMANN, M et al., "Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans", Cancer Immunology Immunotherapy, (20090000), vol. 58, no. 1, pages 95 - 109 | - LÖFFLER A, ET AL, "A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.", BLOOD, The American Society of Hematology, US, US, (20000315), vol. 95, no. 6, ISSN 0006-4971, pages 2098 - 2103 | - Prescribing Information of Campath® (alemtuzumab) from 9/2007 | - Lin Thomas S. et al, "Rituximab in B-cell chronic lymphocytic leukemia.", SEMINARS IN ONCOLOGY, W.B. SAUNDERS, US, US, (20030801), vol. 30, no. 4, ISSN 0093-7754, pages 483 - 492 |